abstract |
The present invention relates to an iRNA (e.g., double-stranded ribonucleic acid (dsRNA)) composition that targets the C5 gene of complement components, and the use of these iRNA (e.g., dsRNA) compositions to inhibit C5 performance and to treat patients with complement components Methods for individuals with C5-related diseases (eg, paroxysmal nocturnal hemoglobinuria). |